- Home
- MYNZ vs SYBX Comparison
MYNZ vs SYBX Comparison
Compare MYNZ & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- SYBX
- Stock Information
- Founded
- MYNZ 2021
- SYBX N/A
- Country
- MYNZ Germany
- SYBX United States
- Employees
- MYNZ N/A
- SYBX N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- SYBX Health Care
- Exchange
- MYNZ Nasdaq
- SYBX Nasdaq
- Market Cap
- MYNZ 16.0M
- SYBX 16.5M
- IPO Year
- MYNZ 2021
- SYBX N/A
- Fundamental
- Price
- MYNZ $5.74
- SYBX $1.36
- Analyst Decision
- MYNZ Buy
- SYBX Hold
- Analyst Count
- MYNZ 3
- SYBX 1
- Target Price
- MYNZ $14.00
- SYBX N/A
- AVG Volume (30 Days)
- MYNZ 361.6K
- SYBX 19.0K
- Earning Date
- MYNZ 04-15-2025
- SYBX 03-18-2025
- Dividend Yield
- MYNZ N/A
- SYBX N/A
- EPS Growth
- MYNZ N/A
- SYBX N/A
- EPS
- MYNZ N/A
- SYBX N/A
- Revenue
- MYNZ $917,203.00
- SYBX $2,777,000.00
- Revenue This Year
- MYNZ $21.95
- SYBX N/A
- Revenue Next Year
- MYNZ $30.77
- SYBX N/A
- P/E Ratio
- MYNZ N/A
- SYBX N/A
- Revenue Growth
- MYNZ 16.23
- SYBX 292.23
- 52 Week Low
- MYNZ $0.18
- SYBX $1.22
- 52 Week High
- MYNZ $8.20
- SYBX $2.04
- Technical
- Relative Strength Index (RSI)
- MYNZ 48.77
- SYBX 45.23
- Support Level
- MYNZ $5.08
- SYBX $1.31
- Resistance Level
- MYNZ $8.16
- SYBX $1.40
- Average True Range (ATR)
- MYNZ 1.10
- SYBX 0.07
- MACD
- MYNZ -0.23
- SYBX 0.00
- Stochastic Oscillator
- MYNZ 21.15
- SYBX 60.61
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.